
Product Data Sheet



Toremifene-d₆

| Cat. No.: | HY-B0005AS | |
|--------------------|---|----|
| Molecular Formula: | $C_{26}H_{22}D_6CINO$ | |
| Molecular Weight: | 412 | |
| Target: | Estrogen Receptor/ERR; Isotope-Labeled Compounds | D↓ |
| Pathway: | Vitamin D Related/Nuclear Receptor; Others | |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. | |



| BIOLOGICAL ACTIVITY | | |
|---------------------|--|--|
| Description | Toremifene-d ₆ is deuterium labeled Toremifene. Toremifene (Z-Toremifene) is a second-generation selective estrogen- receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 μM and 2.6 μM, respectively[1][2]. | |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Gauri J Sabnis, Luciana Macedo, Olga Goloubeva, Toremifene - Atamestane; Alone or In Combination: Predictions from the Preclinical Intratumoral Aromatase Model. J Steroid Biochem Mol Biol. 2008 January; 108(1-2): 1-7.

[3]. Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4.

[4]. Matthew R Smith, Selective Estrogen Receptor Modulators to Prevent Treatment-Related Osteoporosis. Rev Urol. 2005; 7(Suppl 3): S30-S35.

[5]. Taneja SS, Morton R, Barnette G, Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol. 2013 Feb 10;31(5):523-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA